Healthcare / BiotechnologyNasdaqGM
$14.41
-0.18 (-1.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-52.4M · quality 77.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$879M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-11.9%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-832.8%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.0M · net income $-113.6M · FCF $-83.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $10.0M | $10.0M | $10.6M | $8.1M | $8.6M | — | — |
| Net Income | $-113.6M | $-113.6M | $-69.0M | $-58.3M | $-63.1M | $-32.7M | $-6.8M |
| EBITDA | $-155.6M | $-155.6M | $-96.8M | $-71.0M | $-66.3M | — | — |
| EPS | — | — | -1.28 | -1.32 | -1.52 | -1.39 | — |
| Operating Margin | -1576.7% | -1576.7% | -933.6% | -902.9% | -779.0% | — | — |
| Net Margin | -1136.3% | -1136.3% | -651.6% | -721.2% | -732.2% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.07 | 0.08 | — | — |
| Current Ratio | 17.01 | 17.01 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-83.3M | $-83.3M | $-44.2M | $-52.4M | $-49.4M | $-18.5M | $-4.4M |
| Returns | |||||||
| ROE | -11.9% | -11.9% | -6.7% | -16.9% | -19.7% | -8.9% | 46.3% |
| Valuation | |||||||
| P/B | 0.91 | 0.91 | 2.83 | 1.32 | 1.62 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -5.6% | -5.6% | 31.0% | -6.1% | — | — | — |
| EPS Growth | — | — | 3.0% | 13.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-39.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.28 → n/d
Residual
-39.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.